By Andrew Silver SHANGHAI (Reuters) -Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

At Lindora Weight Loss & Wellness, some of their clients have lost as much as 125 pounds. Sarah Hathor and Genia Burdick ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

A novel medication out of Sweden has shown some of the same promise in melting belly fat — without making your stomach churn.

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...

“Our findings show liraglutide may be effective for treating stubborn, high-frequency migraines in patients with obesity, and ...